FDA Gets Dozens Of Complaints After Ranbaxy Recall

Law360, New York (February 15, 2013, 4:56 PM EST) -- In a potential boost for a proposed class action, patients using Ranbaxy Laboratories Ltd.’s generic version of Lipitor have submitted to regulators dozens of complaints, many involving intestinal hemorrhages and abdominal pain, after pills that could contain glass particles were recalled, records obtained by Law360 show.

The U.S. Food and Drug Administration documents, obtained under the Freedom of Information Act, show that more than 50 so-called adverse events have been submitted since the Indian drugmaker on Nov. 9 initiated the voluntary recall, which it described as...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.